Moderna (MRNA) Short-term Investments (2017 - 2026)

Moderna (MRNA) has 10 years of Short-term Investments data on file, last reported at $3.3 billion in Q1 2026.

• Short-term Investments for Q1 2026 came in at $3.3 billion, down 24.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.3 billion (down 24.24% YoY), and the FY2025 annual result was $3.2 billion, down 37.15% from the prior year.
• Short-term Investments climbed to $3.3 billion in Q1 2026 per MRNA's latest filing, from $3.2 billion in the prior quarter.
• Over five years, Short-term Investments peaked at $6.7 billion in Q4 2022 and troughed at $3.2 billion in Q4 2025.
• A 5-year average of $4.9 billion and a median of $5.1 billion in 2022 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2022 and 2025: Short-term Investments surged 120.98% in 2022, then tumbled 37.15% in 2025.
• A 5-year view of Short-term Investments shows it stood at $6.7 billion in 2022, then declined by 14.93% to $5.7 billion in 2023, then dropped by 10.51% to $5.1 billion in 2024, then plunged by 37.15% to $3.2 billion in 2025, then advanced by 2.9% to $3.3 billion in 2026.
• Business Quant data shows MRNA's Short-term Investments at $3.3 billion in Q1 2026, $3.2 billion in Q4 2025, and $3.4 billion in Q3 2025.